Skip to content
Screener

Eikon Therapeutics, Inc. EIKN Net Income

Net Income at other companies

Gilead Sciences logo
Gilead SciencesGILD
-$10.5B-636%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
-$98.54M-36.5%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
-$33.44M+22.8%
OnKure Therapeutics, Inc. logo
OnKure Therapeutics, Inc.OKUR
-$15.16M+4.8%
Immunome logo
ImmunomeIMNM
-$53.84M-29.3%
Erasca, Inc. logo
Erasca, Inc.ERAS
-$183.44M-492%

Other financials

Income statement

See full
Operating income-$87.3M-22.3%
EPS (diluted)-$2.46+90.9%

Balance sheet

See full
Cash & equivalents$161.2M-21.2%
Total debt$254.8M—
Total equity$550.7M+186%
Total assets$850.8M—

Cash flow

See full
Operating cash flow-$89.8M-64.7%
CapEx$262.0K-98.8%
Free cash flow-$90.1M-17.1%

Valuation

See full
Market cap$498.62M-36.3%
Enterprise value$592.29M—

Returns & leverage

See full
Debt / equity0.5×—
Current ratio11.8×—

Where this comes from

Reported directly by Eikon Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The source filing: Eikon Therapeutics, Inc.’s 10-Q, filed May 11, 2026. Open the filing →

Filed
May 11, 2026, 4:13 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-216791

FAQ

What is Eikon Therapeutics, Inc.'s net income?
Eikon Therapeutics, Inc. (EIKN) reported net income of -$82.96M in Q1 2026.
What does net income mean?
The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.

Ask your AI about Eikon Therapeutics, Inc.'s net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude